Thinking of joining a study?

Register your interest

NCT06570889 | RECRUITING | Asthma


VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma
Sponsor:

Professor Klaus Bonnelykke

Information provided by (Responsible Party):

Professor Klaus Bonnelykke

Brief Summary:

The overall aim of the study is to develop a nutritional preventive vitamin D supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that supplementation in higher doses than recommended could reduce the risk of disease development.

Condition or disease

Asthma

Respiratory Tract Infections

Gastrointestinal Infection

Croup

Eczema

Allergy

Wheezing

Fractures, Bone

Development, Child

Cognition Disorders in Children

Psychiatric Diagnosis

Intervention/treatment

Cholecalciferol D3

Olive oil

Phase

PHASE3

Detailed Description:

Randomization of 2000 pregnant women to vitamin D of high-dose (3200 IU/day) vitamin D vs placebo on top of the recommended 400 IU/day. Supplementation begins in gestational week 24 (22-26) until 1 week after delivery. Allocation to the trial will be determined based on the pre-interventional maternal blood levels of EPA+DHA with a dried blood screening test. Women with high levels (above 4.7% of total fatty acids) will be assigned to the vitamin D RCT. Maternal blood will be used for genetic, metabolomic and proteomic profiling. A 3-year follow-up of the children with longitudinal registration of parent reported symptoms, diagnoses, medication use, and hospitalizations will be performed. The primary outcome is persistent wheeze or asthma until age 3 years, with predefined analyses of effect modification by maternal genotypes. Secondary outcomes are lower respiratory tract infections, gastrointestinal infections, croup, troublesome lung symptoms, eczema, allergy, bone fractures, developmental milestones, mental health, cognition, and growth until age 3 years. A follow-up on both primary and secondary outcomes is planned after unblinding, from age 3 to 6 years.

Study Type : INTERVENTIONAL
Estimated Enrollment : 2000 participants
Masking : QUADRUPLE
Primary Purpose : PREVENTION
Official Title : VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma (VICTORY)
Actual Study Start Date : 2024-12-20
Estimated Primary Completion Date : 2026-10
Estimated Study Completion Date : 2033-03

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 45 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: 1
Criteria
* Pregnant Danish women before week 26 with blood levels of EPA+DHA above 4.7% of total fatty acids
  • * No current vitamin D intake above the recommended 400 IU/day
  • * No endocrine-, heart-, kidney- or auto-immune disorders
  • * No disorders requiring treatment with blood thinning medication

  • VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma

    Location Details

    NCT06570889


    Please Choose a site



    How to Participate

    Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

    Locations


    RECRUITING

    Denmark,

    Copenhagen University Hospital of Copenhagen

    Gentofte Municipality, Denmark, DK-2820

    Loading...